Real-world experience of afatinib as first-line therapy for advanced EGFR mutation-positive non-small cell lung cancer in Korea
Authors:
Open Access
- 1 December 2021
- journal article
- research article
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 10 (12) , 4353-4367
Abstract
Real-world experience of afatinib as first-line therapy for advanced EGFR mutation-positive non-small cell lung cancer in Korea Sung Yong Lee, Chang-Min Choi, Yoon Soo Chang, Kye Young Lee, Seung Joon Kim, Sei Hoon Yang, Jeong Seon Ryu, Jeong Eun Lee, Shin Yup Lee, Ji Young Park, Young-Chul Kim, In-Jae Oh, Chi Young Jung, Sang Hoon Lee, Seong Hoon Yoon, Juwhan Choi, Tae Won JangKeywords
This publication has 50 references indexed in Scilit:
- Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trialThe Lancet Oncology, 2014
- Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testingAnnals of Oncology, 2014
- Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR MutationsJournal of Clinical Oncology, 2013
- EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic CharacteristicsMolecular Cancer Therapeutics, 2013
- Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family BlockerThe Journal of Pharmacology and Experimental Therapeutics, 2012
- Oncogene addiction as a foundational rationale for targeted anti‐cancer therapy: promises and perilsEMBO Molecular Medicine, 2011
- Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based AssayClinical Cancer Research, 2011
- BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer modelsOncogene, 2008
- Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or ErlotinibClinical Cancer Research, 2006
- Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or ErlotinibClinical Cancer Research, 2006